Dutch Firm PathoFinder's Multiplex STD Assay Performs Well in Comparative Study
August 18, 2011
Dutch Firm PathoFinder's Multiplex STD Assay Performs Well in Comparative Study
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- On Heels of FDA Approval, Cepheid's Xpert CT/NG Test Performs Well in Multi-Center Clinical Study
March 14, 2013 / PCR Insider - Team Developing Network Biosystems MDx Platform for Biothreat Testing Under Five-Year NIH Grant
June 14, 2012 / PCR Insider - BioHelix Wins STTR Grant to Develop Point-of-Care Version of Boston U MDx Platform
October 13, 2011 / PCR Insider - Cepheid Highlights Strong Uptake of Xpert CT/NG as Q1 Revenues Rise 19 Percent
April 25, 2013 / PCR Insider - Cepheid Xpert CT/NG Gets CLIA 'Moderate Complexity' Rating
January 15, 2013 / GenomeWeb Daily News